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T cell. However, their essential role has
also been excluded by Hikosaka et al.
(2008) via Tcrd/ mice. The possibility
that LTi cells serve as RANKL-producing
cells at the embryo stage would be con-
sistent with previous finding (Rossi et al.,
2007) in which LTi cells were indicated
to promote mTEC maturation.
The data of these three studies have
substantially extended our current under-
standing of the development of mTECs at
both cellular and molecular levels as de-
lineated in Figure 1. However, many ques-
tions still remain elusive. One primary
question is how the TNFRSF signals
work. This question needs to be ad-
dressed for embryonic and postnatal thy-
mus separately, because they might exert
their roles in different checkpoints, e.g.,
mTEC differentiation, maturation, expan-
sion, or organization. The exact role of dif-
ferent TNFRSF signals also remains to be
determined. Second, how does the anti-
gen-specific MHC-TCR interaction regu-
late mTEC development and function? If
TCR specificity prolongs the CD40 and
RANK signaling effect, does this mean
that the TRA-expressing cell would have
prolonged survival or proliferation? How-
ever, this hypothesis would be difficult to
reconcile with previous findings that
Aire+ mTECs have arrested proliferation
and that Aire actually induces apoptosis
in Aire-expressing mTECs (Gray et al.,
2007). If autoreactive T cells are required
for the specific deletion of TRA-express-
ing mTEC, given the diversity of TRAs in
the individual mTEC, how are other TRAs
maintained? Further studies are required
to understand mTEC development and
function in more detail and to explore po-
tential therapeutic interventions.
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Dendritic cells (DCs) play a central role in responding to pathogens. In this issue of Immunity, Aoshi et al.
(2008) highlight the fact that the migratory route DCs take to drive T cell activation is independent of the
architecture of lymphoid tissues.The immune response is critical to control
initial infection against pathogens and to
provide protection from subsequent
infections. The lymph nodes draining
cutaneous or mucosal tissue are the stag-
ing ground for dendritic cells (DCs) that
have been infected or acquired antigen
in the periphery to prime antigen-specific
T cells. In this setting, DCs can either di-
rectly present major histocompatibility
class (MHC) I and II antigens to T cells,
or alternately, transfer antigens to lymph
node resident CD8a+ DCs. The cascade
of antigen trapping, migration, and pre-388 Immunity 29, September 19, 2008 ª200sentation is a highly orchestrated path-
way that relies on specialization of individ-
ual DC subsets to effect activation of T
lymphocytes. The need for this migratory
pathway reflects the microcirculatory
architecture of terminal lymphatics that
drain fluid and antigens from peripheral
tissues and the restricted capacity of DC
themselves to recirculate. In addition,
these migratory cues correctly position
the DCs and T cells for optimal initiation
of the immune response. In contrast, the
spleen lacks afferent lymphatics but has
direct access to blood-borne pathogens8 Elsevier Inc.and antigens that may be captured by
lymphoid-resident DCs and other anti-
gen-presenting cells (APCs). Although
the pathway of fluid and cells is carefully
guided through the lymph node by a series
of anatomically defined sinuses and con-
duits, the spleen has a relatively open
structure allowing flooding of the tissue
with the circulating blood. Despite this dif-
ference, the localization of most splenic
DC subsets is very similar to their distribu-
tion in lymph nodes. The architecture of
the spleen suggests that a defined path-
way for conveying antigens to T cells
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PreviewsFigure 1. Common DC Migratory Route from Peripheral Tissues to Lymph Node and within the Spleen Enable Efficient T Cell Priming
Pathogen-derived antigens are transported by DCs to the draining lymph nodes (left) for presentation to T cells. Blocking DC migration by removal of the infection
site or treatment with inhibitors of DC migration such as agonists of prostaglandin D2 receptor or 2,4-ditrofluorobenzene (DNFB) markedly impairs activation of
CD8+ T cells. When migration of antigen-laden DCs from periphery occurs, they can either initiate the T cell activation cascade themselves or play no part in
presenting antigen directly to T cells. Where migratory DCs present to T cells (scenario 1) this is most efficient to CD4+ T cells, and to a lesser extent to CD8+
T cells. However, where migratory DCs do not present directly to T cells, they provide a source of pathogen antigen for transfer to lymphoid-resident CD8a+
DCs via crosspresentation (scenario 2). In spleen (right), afferent lymphatics are lacking and pathogens gain direct access to secondary lymphoid tissues via
the blood. Despite this, pathogens still appear to gain access to the T cell area by a specific DC migratory pathway. Although it is clear that DCs are required
to transport antigens into the PALS for T cell activation, it is unclear whether different DC populations team up in deciding how to most effectively prime different
T cell responses.may not be necessary despite this lym-
phoid tissue possessing the specific cell
types in the correct anatomical locations
to do so. In this issue of Immunity, Aoshi
et al. (2008) directly examine the require-
ment of DC migration for the induction
of T cell immunity to blood-borne patho-
gens in spleen. Strikingly, their work
concludes that a DC migratory pathway,
analogous to that described for lymph no-
des, is essential for the development of
CD8+ T cell responses to hematogenously
spread Listeria monocytogenes (Lm)
(Figure 1).
The spleen acts as an important site for
the filtration of, and initiation of the im-
mune response against, pathogens that
gain access to the body via the skin or
gut and are subsequently disseminated
throughout the body in the blood (for ex-
ample Plasmodium spp and Salmonella
spp). Splenic architecture is organized
into two distinct compartments: the white
pulp (WP) containing B cell follicles, the
T cell area, and the periarteriolar lymphoid
sheath (PALS); and the red pulp (RP),
a blood-filled space between the folliclesof the WP that includes the complex
venous system, macrophages, reticular
fibroblasts, and some lymphocytes. The
marginal zone (MZ) separates the WP
and RP and surrounds the B cell follicles.
Macrophages situated in the MZ and sim-
ilar cells lining the subcapsular sinus of
lymph nodes are emerging as important
phagocytic cells involved in initial antigen
trapping (Hickman et al., 2008). Despite
this, only DCs appear to participate in
initiation of CD8+ T cell activation.
Whether splenic DCs have a distinct mi-
gratory pathway analogous to that seen
in lymph nodes ensuring effective T cell
activation has not been clear, especially
because DCs can potentially passively
enter the spleen via the circulation. Aoshi
et al. (2008) have addressed this question
by using elegant cellular-labeling ap-
proaches to analyze the migratory behav-
ior and priming capacity of monocyte and
DCs after infection of mice with the intra-
cellular Gram-positive bacterium Listeria
monocytogenes (Lm). Lm is a well-de-
fined model used to study innate and
adaptive immunity to a pathogen that isImmunity 29, Sexperimentally disseminated via the blood.
Strikingly, MZ macrophages rapidly be-
came infected with Lm but did not appear
to migrate to the region of the PALS—the
dominant location of T cells in spleen. In-
stead, the small number of infected DCs
also located in the MZ undertook a migra-
tory route from the MZ to the PALS where
engagement of T cells ensued.
To initially examine DC migration, the
authors utilized pertussis toxin (Ptx) treat-
ment that uncouples G protein-signaling
pathways. This approach does not selec-
tively interfere with DC migration, but
treatment of mice prior to the adoptive
transfer of responder T cells resulted in
impairment of DC, but not T cell, behavior.
Despite this, the approach does not dis-
count other potentially important effects
on DCs such as changes in maturation,
cytokine production, and Toll-like recep-
tor signaling, known to be affected by
Ptx, or effects on other cell types that
might play a role in transporting bacteria.
To provide further evidence that DC
migration was required for bacterial entry
and antigen presentation in PALS, twoeptember 19, 2008 ª2008 Elsevier Inc. 389
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authors made use of the key observation
that after depletion of macrophages and
DCs in diptheria toxin receptor-express-
ing transgenic mice or via clodronate lipo-
some-mediated ablation, these cell types
recolonize their niches at differing rates.
Although both cell types are depleted at
2 days, DCs rapidly return whereas mac-
rophages remain depleted for at least
a week. This scenario allowed indepen-
dent analysis of the contribution of DCs
to translocation of bacterial to the
PALS, lending support for their earlier ob-
servations. Although molecular regulation
of bacterial translocation was not dis-
sected in this work, the selective effects
of Ptx on DCs, but not T cells, implies
that chemokine receptor signaling (per-
haps CCR7 and CCR5) provides a molec-
ular guide for DC migration within the
spleen (Randolph et al., 2008). It will be
important to determine more precisely
the key regulators of DC migration along
this pathway. It will also be intriguing to
determine whether this migratory process
is constitutive as in lymph nodes or is in-
voked only when a potent inflammatory
stimulus is received.
Khanna et al. (2007) recently provided
the first in vivo description of the multi-
stage nature of CD8+ T cell activation to
Lm in spleen via elegant in situ two-pho-
ton imaging. Visualization of Lm-specific
CD8+ T cells revealed that initial activation
occurred at the borders of the T and B cell
zones. This was followed by cluster for-
mation with APC, principally involving
the PALS, followed by relocalization of
T cells. Detailed analysis of the role of dif-390 Immunity 29, September 19, 2008 ª200ferent DC subsets was not investigated in
this study or that of Aoshi et al. (2008), but
parallels between the migratory route of
DC in lymph node and spleen suggest
that such an analysis will be important
(Figure 1). CD8a+ DCs have been shown
previously to prime CD8+ T cell re-
sponses, suggesting that these DCs play
a central role in the response to Lm (Belz
et al., 2005). It was also this DC subset
that was found to almost exclusively con-
tain live Lm and which has been strongly
implicated as responsible for the initial
trapping of bacteria (Neuenhahn et al.,
2006). This suggests that infected
CD8a+ DCs directly present MHC class I
peptides to T cells. How this occurs is
somewhat difficult to envisage—CD8a+
DCs in spleen are localized to the PALS
and there is little evidence for substantial
migration by this DC subset. The migra-
tory capacity of CD8a+ DCs, however,
has been examined only in lymph nodes,
so it remains possible that their potential,
or that of precursors within the spleen,
may be different. By contrast, CD8a
DCs largely reside in the RP and MZ
such that they are ideally situated to pick
up and ferry antigens to CD8a+ as has
been shown to occur in the periphery.
Further studies will be needed to investi-
gate the migratory potential of different
DC subsets and their specific roles in the
capture and presentation pathway in
spleen to determine whether transfer of
antigens between DCs, first described
by K. Inaba (Inaba et al., 1998) and dem-
onstrated by others (Allan et al., 2006;
Belz et al., 2004), is also a feature of
T cell activation in spleen.8 Elsevier Inc.This work of Aoshi et al. (2008) high-
lights that despite apparent differences
in the architecture of lymphoid organs,
DC capture of antigen and migration to
areas where DC-T cell colocalization can
occur may be essential to promote effec-
tive adaptive immunity in all secondary
lymphoid tissues. Whether DCs team up
to effect this process remains to be eluci-
dated.
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